Long-Term Outcome of Children and Adolescents With Anti-Phospholipid Antibodies (APL)
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Long-Term Outcome of Children and Adolescents With Anti-Phospholipid Antibodies|
- Evaluate changes and improve ability to determine the long-term outcome of affected individuals [ Time Frame: Ten years ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||May 2001|
|Study Completion Date:||June 2011|
Those with a condition
- Determine the incidence, and time frame, for aquiring aPL in a cohort of aPL-negative pediatric SLE subjects.
- Determine the incidence, and time frame, for developing a first APS-associated complication among SLE subjects with detectable aPL.
- Determine the incidence, and time frame, for developing a second APS-associated event among subjects with a history of an APS-associated event.
- Determine the incidence, and time frame, for developing SLE among subjects with a history of an APS-associated event in the absence of SLE.
- Identify laboratory and clinical predictors for the events described in aims 1-4.Research Design and Methods:
This is a prospective cohort study to determine the risk of developing aPL or APS-related symptoms in a young group of SLE and APS subjects. Patients will be followed over a ten year period and will undergo annual serologic and clinical evaluations to identify disease progression.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00581763
|United States, California|
|University of California, San Francisco|
|San Francisco, California, United States, 94143|
|Principal Investigator:||Emily von Scheven||University of California, San Francisco|